Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-B381 phase I/II study in advanced solid tumors
ChiCTR2600135484Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ICP-B381 in prostate cancer (PCa), Ewing sarcoma, transitional cell carcinoma (TCC) and 1 more (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Adverse events and serious adverse events, Immunogenicity and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ICP-B381
03
Conditions
prostate cancer (PCa)Ewing sarcomatransitional cell carcinoma (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600135484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135484.